Ikänik gets the go-ahead for CBD skin care launch in Colombia The cannabis company, with a specialty in indoor cultivation, has just commercialized 6 CBD skin care products for sale in Latin America.
“We are proud to have completed this major milestone and have positioned ourselves to be a leader and cornerstone of product quality within the global marketplace, with an initial emphasis in Latin America and Europe.” Borja Sanz de Madrid, President of Ikänik Farms International, Inc., tells the press.
Finding a market for cannabis beauty in LATAM
Like many companies in the cannabinoids business, Ikänik is leveraging opportunities in the LATAM region to grow its business.
Ikänik Farms Registers and Commercializes 6 CBD Products Eligible for Sale in Colombia, Ecuador, Bolivia & Peru
News provided by
Share this article
Company or
Ikänik Farms ) is pleased to announce that its wholly owned, Colombian subsidiary Pideka SAS (
Pideka ), has completed the registration and commercialization process of six cannabis-based cosmetic products through the National Institute of Drug and Food Surveillance (INVIMA), the governing body in Colombia responsible new product registrations. We are excited to open the door to multiple countries concurrent with our product registrations and look forward to better serving the Latin American markets in the near future. said Brian Baca, CEO of Ikänik Farms.
/PRNewswire/ THC is perhaps the most well-known cannabinoid within cannabis. THC, short for tetrahydrocannabinol, is famously responsible for cannabis s.
Colombian Regulator Approves Start of Germany s CureVac Phase 3 Trials Fri 29th January 2021 | 01:40 PM
MOSCOW (UrduPoint News / Sputnik - 29th January, 2021) Colombia has approved the start of phase 3 trials of the German CureVac vaccine against COVID-19, the Colombian National Institute of Drug and food Surveillance (INVIMA) said. The National Institute of Drug and Food Surveillance under the resolution . approved the start of phase IIb/III clinical trials in Colombia of ARNm CVnCoV vaccine which is applied in two doses to adults over the age of 18, the authority said in a press release on Thursday.
According to the INVIMA, the clinical trials are also underway in Belgium, Germany and the Netherlands. Their overall duration is 28 months.